Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Waltham, Massachusetts, focused on developing next-generation therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company's mission is to redefine the standard of care in these areas by pioneering long-acting antibodies and antibody combinations.

Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7 (SPY001), TL1A (SPY002, SPY072), and IL-23 (SPY003). The company is also developing multi-antibody combinations such as SPY120 (SPY001 + SPY002), SPY130 (SPY001 + SPY003), and SPY230 (SPY002 + SPY003), aiming to address distinct disease drivers and offer improved efficacy and convenience.

Led by CEO Cameron Turtle, Spyre Therapeutics has been active in securing capital through public offerings, including a $463.5 million offering in April 2026. The company reported positive Phase 2 SKYLINE data for SPY001 in ulcerative colitis in April 2026, demonstrating a 40% clinical remission rate. Spyre also anticipates topline data for its SPY072 program in rheumatoid arthritis in Q3 2026. Analysts generally hold a "Strong Buy" consensus rating for the stock, with an average price target of $85.08.